Understanding how glucocorticoid gene regulation affects leukemia treatment
Official title: Deciphering the underlying structure of the glucocorticoid gene regulatory network
Funded at St. Jude Children's Research Hospital · NIH-11025209 · Data updated 2026-11-12
This study is looking at how certain genes affect how well glucocorticoid medications work for patients with B-cell acute lymphoblastic leukemia, especially for those who struggle with treatment resistance, to help find better ways to improve their response to these important drugs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Jude Children's Research Hospital NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $814,368 |
| NIH project number | 1R01HG013981-01 |
| Project ID | NIH-11025209 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with B-cell acute lymphoblastic leukemia who are undergoing glucocorticoid treatment.
✕Less likely to help
Patients with other types of leukemia or those not receiving glucocorticoid therapy may not benefit from this research.
What this research studies
This research investigates the glucocorticoid gene regulatory network, which plays a crucial role in how cells respond to glucocorticoids, a type of steroid medication commonly used to treat conditions like leukemia and autoimmune diseases. By examining the genetic elements that influence this network, researchers aim to uncover why some patients with B-cell acute lymphoblastic leukemia (B-ALL) develop resistance to glucocorticoid treatment. The study employs advanced techniques to analyze genetic variations and their effects on cell behavior, particularly focusing on apoptosis, or programmed cell death, which is essential for effective cancer treatment. Patients may benefit from a deeper understanding of their treatment responses and potential new strategies to overcome drug resistance.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with B-ALL, particularly those who experience glucocorticoid resistance.
How similar studies have gone: Previous research has shown that understanding gene regulatory networks can lead to significant advancements in treatment strategies for various cancers, indicating a promising avenue for this study.
Where this research is happening
-
St. Jude Children's Research Hospital
Memphis, United States Active
Researchers
- Principal investigator: Savic, Daniel — St. Jude Children's Research Hospital
- Study coordinator: Savic, Daniel
Related research
Other NIH-funded projects on the same topics.
-
Investigating frailty and aging in childhood cancer survivors
This study is looking at childhood cancer survivors to see how they might face health challenges similar to older adults as they grow up, and it aims to find ways to help them stay strong and healthy by exploring treatments that could improve their well-being.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Accessible, label-free optical imaging to reveal disease signals
A brain-friendly, patient-centered imaging approach aims to uncover hidden disease signals in cells and tissues without labels or dyes.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Blocking cancer-causing cMYC tricks after pregnancy changes in the breast
Researchers are testing how pregnancy and aging reshape the breast before cancer risk, using patient-reinformed models to see if it changes how dangerous cMYC signals behave.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.